Literature DB >> 34201284

Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologist's Role.

Mina Komuta1,2,3.   

Abstract

Primary liver cancers (PLCs) mainly comprise hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and cHCC-CCA. Combined HCC-CCA and small duct type iCCA show similar clinical presentations, and their histological features are more complex than seen in HCC. Therefore, while their treatment strategy differs, it is difficult to properly diagnose these tumors. Currently, HCC is the only tumor that can be treated by liver transplantation. In addition, small duct type iCCA harbors IDH1/2 mutations and FGFR2 fusions, which can be used for targeted therapy. Thus, improving diagnostic accuracy is crucial. A further point to note is that PLCs often present as multiple liver tumors, and they can be a combination of different types of PLCs or HCCs. In the case of HCCs, two different scenarios are possible, namely intrahepatic metastasis, or multicentric occurrence. Therefore, it is essential to characterize the type of multiple liver tumors. This review aims to clarify the pathological features of HCC, iCCA and cHCC-CCA, including their diagnostic pitfalls and clinical relevance. It is designed to be of use to clinicians who are dealing with PLCs, to provide a better understanding of the pathology of these tumors, and to enable a more accurate diagnosis and optimal treatment choice.

Entities:  

Keywords:  cholangiocarcinoma; cholangiolocellular carcinoma; combined hepatocellular-cholangiocarcinoma; differential diagnosis; hepatocellular carcinoma; keratin 19 positive hepatocellular carcinoma; liver cancer; molecular profiles; pathological diagnosis; tumor heterogeneity

Year:  2021        PMID: 34201284     DOI: 10.3390/cancers13122871

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations.

Authors:  Tiemo S Gerber; Lukas Müller; Fabian Bartsch; Lisa-Katharina Gröger; Mario Schindeldecker; Dirk A Ridder; Benjamin Goeppert; Markus Möhler; Christoph Dueber; Hauke Lang; Wilfried Roth; Roman Kloeckner; Beate K Straub
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 2.  Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.

Authors:  Mina Komuta
Journal:  Clin Mol Hepatol       Date:  2022-01-14

3.  Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis.

Authors:  Qian Chen; Sibo Yang; Yewei Zhang; Bo Li; Huanming Xu; Shi Zuo
Journal:  Biomed Res Int       Date:  2022-01-28       Impact factor: 3.411

4.  Promising role of liver transplantation in patients with combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis.

Authors:  Xiaoyuan Chen; Shiquan Sun; Yiwei Lu; Xiaoli Shi; Ziyi Wang; Xuejiao Chen; Guoyong Han; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  Ann Transl Med       Date:  2022-04

Review 5.  Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.

Authors:  Joon Hyuk Choi; Jae Y Ro
Journal:  Biomedicines       Date:  2022-07-29

Review 6.  Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach.

Authors:  Felix Krenzien; Nora Nevermann; Alina Krombholz; Christian Benzing; Philipp Haber; Uli Fehrenbach; Georg Lurje; Uwe Pelzer; Johann Pratschke; Moritz Schmelzle; Wenzel Schöning
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.